MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs...
Cancer
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the...
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and...
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31,...
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus.Philadelphia,...
BillionToOne Expands Executive Team to Support Growth of UNITY and Northstar Platforms
New Leaders Bring Deep Expertise in Operational Efficiency MENLO PARK, Calif., Aug. 1, 2025 /PRNewswire/ -- BillionToOne, Inc., a molecular...
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation...
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on...
Is DEA Administrator Terry Cole Just Another Anti Marijuana Crooner in A Suit? Or A Cannabis Policy Reformer
Newly confirmed DEA Administrator Terrance Cole faces a defining choice: Will he break ranks with the agency's deeply entrenched anti-cannabis...
Lumitex Releases 2025 State of Medical Lighting Report
Cutting-Edge Insights for Advancing Healthcare Lighting Solutions CLEVELAND, Ohio, July 31, 2025 /PRNewswire/ -- Lumitex, a global leader in innovative...
Your Tumor’s Best Treatment? A Space-Based Test Could Tell You
With new NASA and NSF funding, Encapsulate is building on its ISS National Lab-sponsored research to bring personalized cancer diagnostics...
CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of...
Elucent Medical Marks 25,000 Lives Impacted Through EnVisio® Technology
MINNEAPOLIS, July 31, 2025 (GLOBE NEWSWIRE) -- Elucent Medical is proud to announce that more than 25,000 successful procedures have...
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing...
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31,...
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...